The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma
Jeffrey E. Green(Genesis Foundation), Christine Couldrey(Livestock Improvement Corporation), Miriam R. Anver(Science Applications International Corporation (United States)), Cheryl L. Jorcyk(Boise State University), Jon M. Wigginton(Bristol-Myers Squibb (United States)), Masaaki Shibata(Yamaha (Japan)), Minling Liu(Genesis Foundation), Eiko Shibata(Genesis Foundation), Weili Wang(Genesis Foundation), Stanislaw J. Kaczmarczyk(Genesis Foundation), Zi-yao Liu(Genesis Foundation), Alfonso Calvo(Instituto de Salud Carlos III), Robert H. Wiltrout(Frederick National Laboratory for Cancer Research), Katsuhide Yoshidome(Genesis Foundation)
Cited by 265
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k